Lung Cancer
August 2020 Vol 11, No 8 | August 5, 2020
Vaping devices, also known as e-cigarettes, are the new epidemic among young people in the United States, according to Nancy Sayegh-Rooney, RN, a lung nurse navigator on Staten Island, NY, and a Certified Tobacco Treatment Specialist who educates students in middle school and high school about the dangers of vaping.
July 2020 Vol 11, No 7 | July 9, 2020
On May 15, 2020, the FDA approved a new indication for the first immunotherapy combination with the PD-1 inhibitor nivolumab (Opdivo; BMS) and the CTLA-4 inhibitor ipilimumab (Yervoy; BMS) for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and PD-L1 expression of ≥1%, as determined by an FDA-approved test, but without EGFR or ALK genomic translocations.
July 2020 Vol 11, No 7 | July 9, 2020
Data from the TRACERx lung study suggest that
circulating tumor DNA (ctDNA) may be a
biomarker for the detection of postsurgical minimal
residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which
patients are at higher risk of relapse and require more
aggressive adjuvant therapy.
July 2020 Vol 11, No 7 | July 9, 2020
Exploring second opinions allows patients to become more informed and secure in their choice of which treatment to pursue.
June 2020 Vol 11, No 6 | June 3, 2020
Who stands to benefit from lung cancer screening? Click here to find out.
May 2020 Vol 11, No 5 | May 7, 2020
As part of a mesothelioma advisory group, I and
approximately 10 doctors from across the United
States provide expert opinions on treatments
and modalities for mesothelioma.
March 2020 Vol 11, No 3 | March 2, 2020
Nutrition plays an important role throughout the continuum of lung cancer. It is well documented that the best protection from lung cancer is to avoid smoking, but it is also protective to eat a diet rich in fruits and vegetables.
Web Exclusives | February 4, 2020
On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020.
February 2020 Vol 11, No 2 | January 27, 2020
Eye-opening comments from the people who stand to benefit from navigation most. Here’s what they said.
January 2020 Vol 11, No 1 | December 26, 2019
Compared with other standard treatments, untreated patients with advanced non–small-cell lung cancer (NSCLC) who also have an EGFR mutation live longer when treated with osimertinib, according to a new study.